List of Duexis drug patents

Duexis is owned by Horizon.

Duexis contains Famotidine; Ibuprofen.

Duexis has a total of 5 drug patents out of which 0 drug patents have expired.

Duexis was authorised for market use on 23 April, 2011.

Duexis is available in tablet;oral dosage forms.

Duexis can be used as relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications.

The generics of Duexis are possible to be released after 18 July, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309127 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(3 years from now)

US8067451 HORIZON Methods and medicaments for administration of ibuprofen
Jul, 2026

(3 years from now)

US8501228 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(3 years from now)

US8318202 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(3 years from now)

US8449910 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(3 years from now)

Drugs and Companies using FAMOTIDINE; IBUPROFEN ingredient

Market Authorisation Date: 23 April, 2011

Treatment: Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications

Dosage: TABLET;ORAL

How can I launch a generic of DUEXIS before it's patent expiration?
More Information on Dosage

DUEXIS family patents

25

United States

3

European Union

2

Israel

2

Japan

2

New Zealand

2

Canada

2

Australia

2

China

1

Brazil

1

Portugal

1

South Africa

1

Denmark

1

Austria

1

Spain

1

Poland

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in